Company news
Coherus Oncology, Inc. news in 2021
Coherus Oncology, Inc.'s news releases, calls and decks from 2021, newest first.
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
December 19, 2021
Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer
December 16, 2021
Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
November 14, 2021
Coherus BioSciences Reports Third Quarter 2021 Results
November 7, 2021
Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022
November 4, 2021
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
October 31, 2021
Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th
October 28, 2021
Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson
October 10, 2021
Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial
October 4, 2021
Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review
September 30, 2021
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal...
September 15, 2021
Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
September 14, 2021
Coherus BioSciences Announces Upcoming Medical Conference Presentations
September 7, 2021
Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
August 31, 2021
Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
August 17, 2021
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
August 4, 2021
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board
July 20, 2021
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
June 3, 2021
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
May 5, 2021
Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th
April 29, 2021
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma
April 22, 2021
Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences
April 19, 2021
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
March 2, 2021
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
February 23, 2021
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
February 16, 2021
Coherus Announces CFO Transition Plans
February 15, 2021
Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
February 1, 2021
Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences’ PD-1, toripalimab, in United States and Canada
January 31, 2021
Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors
January 6, 2021